| Previous 10 | Next 10 |
Ad
DTIL News and Press Precision BioSciences Inc. From...
News | Precision BioSciences Inc. (NASDAQ:DTIL)
-
2025-02-19 07:53:44 ET More on Precision BioSciences Precision Bio rises after gene editing data: BMO upgrades (update) Seeking Alpha’s Quant Rating on Precision BioSciences Historical earnings data for Precision BioSciences Financial information for P...
-
2025-02-12 03:56:54 ET More on MaxCyte MaxCyte acquires SeQure Dx MaxCyte estimates higher Q4 core revenue from last year Seeking Alpha’s Quant Rating on MaxCyte Historical earnings data for MaxCyte Financial information for MaxCyte R...
-
2025-01-10 07:03:27 ET More on Precision BioSciences Seeking Alpha’s Quant Rating on Precision BioSciences Historical earnings data for Precision BioSciences Financial information for Precision BioSciences Read the full article on Seeking Alpha ...
-
- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no significant clinical safety concerns - Insertion of a functional OTC gene through ARC...
-
First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 10 13 GC/kg) of ECUR-506 from three months post exposure to the end of study (six months post exposure) as demonstrated by the removal of ...
-
- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024 - ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected...
-
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. ...
-
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and...
-
2024-11-06 05:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2024-11-04 07:11:47 ET More on Precision BioSciences Seeking Alpha’s Quant Rating on Precision BioSciences Historical earnings data for Precision BioSciences Financial information for Precision BioSciences Read the full article on Seeking Alpha ...
Stock Information
Get DTIL Alerts
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NASDAQ Market:
3.23% G/L:
$4.55 Last:
182,307 Volume:
$4.79 Open:
$4.55 Close:
Precision BioSciences Inc. Website:
Ad
-
Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...
-
2025-05-14 18:48:07 ET Precision BioSciences, Inc. (DTIL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.06%. The average open to low on the day of earnings was -7.50%. The average op...
-
2025-05-14 18:43:07 ET Precision BioSciences, Inc. (DTIL) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in DTIL stock price following earnings has averaged ±3.41% , with a median of 1.6...